StemCell Pharma, Inc. Proprietary Implant Hopes To Benefit Early Alzheimer's Patients Using Stem Cells Without Politics And Controversy
10/19/2005 5:10:11 PM
CHICAGO--(BUSINESS WIRE)--May 11, 2005--StemCell Pharma, Inc. is offering hope to early Alzheimer's patients by delivering young cells to mature bodies. Utilizing an innovative, proprietary placenta/stem cell "Implant," this procedure may be performed in a physician's office. This approach addresses the major symptoms of Alzheimer's which are depression, memory loss, impaired immune system, and anemia.
Originally developed by the Filatov Institute in Odessa, Crimea in the USSR, the technique has been updated by Alfred T. Sapse, MD (r). Dr. Sapse studied under Russian scientist Vladimir Petrovich Filatov who used human placentas and umbilical cords in the treatment of many diseases. Considerable success in the prevention and treatment of aging and aging diseases was documented by the Filatov Institute and Dr. Sapse in his native Romania. Filatov Institute released 300 million ampoules of tissue therapy drugs in clinical settings.
comments powered by